Use of hydroxycarbamide for preventing retinal nonperfusion
US10617658B2 · kind B2 · utility
Assignees
- CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- IMAGINE—INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES
- ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP)
- UNIVERSITE DE PARIS DESCARTES
Inventors
Key dates
| Filing date | Aug 8, 2016 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | Aug 8, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.